Page last updated: 2024-08-25

grepafloxacin and ciprofloxacin

grepafloxacin has been researched along with ciprofloxacin in 48 studies

Research

Studies (48)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	19 (39.58)	18.2507
2000's	21 (43.75)	29.6817
2010's	7 (14.58)	24.3611
2020's	1 (2.08)	2.80

Authors

Authors	Studies
Domagala, JM; Hagen, SE; Heifetz, CL; Johnson, J	1
Keserü, GM	1
Inui, K; Saito, H; Yamaguchi, H; Yano, I	1
Nagashima, R; Nishikawa, T; Tobita, M	1
Morgan-Linnell, SK; Zechiedrich, L	1
Jia, L; Sun, H	1
Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E	1
Brillault, J; Couet, W; De Castro, WV	1
Anquetin, G; Biot, C; Dive, D; Dubar, F; Khalife, J; Pradines, B	1
Sen, S; Sinha, N	1
Imai, YN; Oiki, S; Ryu, S	1
Allanki, AD; Chandra Shekhar, A; Narsaiah, B; Shanthan Rao, P; Sijwali, PS	1
Blaskovich, MAT; Pham, TDM; Ziora, ZM	1
Dana, S; Dhar, SK; Gurung, SK; Kumar, S; Mondal, N; Mukhopadhyay, P; Valissery, P	1
Mitsuhashi, S; Wakebe, H	1
Sanders, CC; Thomson, KS	1
Arduino, RC; Frosolono, M; Murray, BE	1
Appelbaum, PC; Jacobs, MR; Spangler, SK	1
Neumann, T; Patton, M; Reichart, C; Zenilman, JM	1
Andrews, JM; Brenwald, N; Wise, R	1
Barry, AL; Fuchs, PC	1
Barry, AL; Brown, SD; Fuchs, PC	1
Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H	1
Goldsmith, CE; Moore, JE; Murphy, PG	1
Andrews, JM; Wise, R	1
Dawe, R; Ferguson, J	1
Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR	1
Hajime, N; Kamberi, M; Kamberi, P; Nakamura, K; Nakano, S; Uemura, N	1
Bébéar, C; Bébéar, CM; Leblanc, F; Renaudin, H; Schaeverbeke, T	1
Hashimoto, K; Minami, T; Owen, K; Takizawa, T; Yamashita, S	1
Fourche, J; Leblanc, F; Maugein, J; Pellegrin, JL; Vacher, S	1
Johnson, AP; Stewart, BA; Woodford, N	1
Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C	1
Fraser, S; Mair, D; Patmore, L; Templeton, A	1
Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P	1
Johnson, AP; Livermore, DM; Warner, M	1
Ball, P	1
Kanoh, S; Kondo, M; Nagai, A; Nagano, Y; Tamaoki, J	1
Fisher, LM; Morris, JE; Pan, XS	1
Hara, T; Kanemitsu, K; Shimada, J; Takemura, H; Yamamoto, H	1
Evans, ME	1
Lowes, S; Simmons, NL	1
Chen, J; Deguchi, Y; Morimoto, K; Sakai, S; Sun, J; Tauchi, Y; Zhang, R	1
Bermejo, MV; Garrigues, TM; Merino, V; Montalar-Montero, M; Nalda-Molina, R; Rodríguez-Ibáñez, M	1
Dalhoff, A; Shalit, I	1
Bermejo, M; Garrigues, TM; Merino, V; Montalar-Montero, M; Rodríguez-Ibáñez, M; Sánchez-Castaño, G	1
Asari, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Osaka, Y; Yasuda, S	1
Brillault, J; Couet, W; Gobin, P; Gontijo, AV; Grégoire, N; Lamarche, I; Marchand, S	1

Reviews

2 review(s) available for grepafloxacin and ciprofloxacin

Article	Year
Quinolone antibiotics. MedChemComm, 2019, Oct-01, Volume: 10, Issue:10 Topics:	2019
Immunomodulatory effects of quinolones. The Lancet. Infectious diseases, 2003, Volume: 3, Issue:6 Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Cytokines; Fluoroquinolones; Humans; Immune System; Models, Animal; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines	2003

Trials

2 trial(s) available for grepafloxacin and ciprofloxacin

Article	Year
Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Bronchodilator Agents; Chronic Disease; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Theophylline; Treatment Outcome	1998
Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. The Journal of antimicrobial chemotherapy, 1997, Volume: 40 Suppl A Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Dermatitis, Phototoxic; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Double-Blind Method; Drug Administration Schedule; Erythema; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Placebos; Quinolones; Reference Standards; Skin Pigmentation; Ultraviolet Rays	1997

Article

Year

Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.

Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:1

Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Bronchodilator Agents; Chronic Disease; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Theophylline; Treatment Outcome

1998

Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin.

The Journal of antimicrobial chemotherapy, 1997, Volume: 40 Suppl A

Topics: Adolescent; Adult; Anti-Infective Agents; Ciprofloxacin; Dermatitis, Phototoxic; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Double-Blind Method; Drug Administration Schedule; Erythema; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Placebos; Quinolones; Reference Standards; Skin Pigmentation; Ultraviolet Rays

1997

Other Studies

44 other study(ies) available for grepafloxacin and ciprofloxacin

Article	Year
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids. Journal of medicinal chemistry, 1991, Volume: 34, Issue:3 Topics: 4-Quinolones; Anti-Infective Agents; Chemical Phenomena; Chemistry; Gram-Negative Bacteria; Gram-Positive Bacteria; Methylation; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship	1991
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship	2003
Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharmaceutical research, 2004, Volume: 21, Issue:2 Topics: Acute Kidney Injury; Animals; Anti-Infective Agents; Antineoplastic Agents; Bile Ducts; Biological Availability; Blotting, Western; Caco-2 Cells; Ciprofloxacin; Cisplatin; Duodenum; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Ofloxacin; Piperazines; Rats; Rats, Wistar; Time Factors	2004
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11 Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated	2005
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:11 Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation	2007
Support vector machines classification of hERG liabilities based on atom types. Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11 Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve	2008
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes	2010
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:1 Topics: Absorption; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport, Active; Cell Line; Cell Membrane Permeability; Cyclosporins; Diffusion; Drug Interactions; Drug Resistance, Bacterial; Epithelial Cells; Fluoroquinolones; Kinetics; Lipids; Lung	2010
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach. Journal of medicinal chemistry, 2009, Dec-24, Volume: 52, Issue:24 Topics: Aminoquinolines; Antimalarials; Ciprofloxacin; Ferrous Compounds; Metallocenes; Plasmodium falciparum; Prodrugs	2009
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. European journal of medicinal chemistry, 2011, Volume: 46, Issue:2 Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship	2011
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel. Bioorganic & medicinal chemistry letters, 2013, Jul-01, Volume: 23, Issue:13 Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship	2013
Emergence of pyrido quinoxalines as new family of antimalarial agents. European journal of medicinal chemistry, 2014, Apr-22, Volume: 77 Topics: Antimalarials; Dose-Response Relationship, Drug; Erythrocytes; Humans; Molecular Structure; Plasmodium falciparum; Pyrazines; Quinoxalines; Structure-Activity Relationship	2014
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity. ACS medicinal chemistry letters, 2020, Jul-09, Volume: 11, Issue:7 Topics:	2020
Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrobial agents and chemotherapy, 1992, Volume: 36, Issue:10 Topics: Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerases, Type II; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Piperazines; Quinolones; Staphylococcus aureus	1992
Dissociated resistance among fluoroquinolones. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:9 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Quinolones	1994
In-vitro activity of OPC-17116 against bacterial enteric pathogens. The Journal of antimicrobial chemotherapy, 1994, Volume: 34, Issue:3 Topics: Anti-Infective Agents; Ciprofloxacin; Enterobacteriaceae; Escherichia coli; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperazines; Quinolones; Tetracycline; Trimethoprim	1994
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:10 Topics: Anti-Infective Agents; Bacteria, Anaerobic; Cefoxitin; Ciprofloxacin; Fluoroquinolones; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperazines; Quinolones; Tazobactam	1994
Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Antimicrobial agents and chemotherapy, 1993, Volume: 37, Issue:10 Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Ofloxacin; Penicillin Resistance; Piperazines; Quinolones; Tetracycline Resistance	1993
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. The Journal of antimicrobial chemotherapy, 1993, Volume: 31, Issue:4 Topics: Amoxicillin; Anti-Infective Agents; Bacteroides fragilis; Cefaclor; Chlamydia trachomatis; Chlamydophila pneumoniae; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Norfloxacin; Piperazines; Protein Binding; Quinolones; Staphylococcus	1993
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. Journal of chemotherapy (Florence, Italy), 1997, Volume: 9, Issue:1 Topics: Anti-Infective Agents; Bacteria, Anaerobic; Ciprofloxacin; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mutation; Ofloxacin; Piperazines; Quinolones	1997
Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones? The Journal of antimicrobial chemotherapy, 1997, Volume: 39, Issue:4 Topics: Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quinolones; Reproducibility of Results	1997
Pneumococcal resistance in the UK. The Journal of antimicrobial chemotherapy, 1997, Volume: 40 Suppl A Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cephalosporins; Chloramphenicol; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Macrolides; Microbial Sensitivity Tests; Northern Ireland; Ofloxacin; Oxacillin; Penicillin Resistance; Penicillins; Piperazines; Pneumococcal Infections; Quinolones; Retrospective Studies; Streptococcus pneumoniae; Tetracycline	1997
The activity of grepafloxacin against respiratory pathogens in the UK. The Journal of antimicrobial chemotherapy, 1997, Volume: 40 Suppl A Topics: Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Drug Resistance, Microbial; England; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillin Resistance; Penicillins; Piperazines; Quinolones; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae	1997
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:2 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin	1999
Simultaneous determination of grepafloxacin, ciprofloxacin, and theophylline in human plasma and urine by HPLC. Therapeutic drug monitoring, 1999, Volume: 21, Issue:3 Topics: Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Interactions; Drug Monitoring; Fluoroquinolones; Humans; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Theophylline	1999
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas. The Journal of antimicrobial chemotherapy, 1999, Volume: 43, Issue:5 Topics: Anti-Infective Agents; Ciprofloxacin; Doxycycline; Erythromycin; Fluoroquinolones; Microbial Sensitivity Tests; Mycoplasma; Ofloxacin; Piperazines; Ureaplasma urealyticum	1999
The comparative arthropathy of fluoroquinolones in dogs. Human & experimental toxicology, 1999, Volume: 18, Issue:6 Topics: Animals; Anti-Infective Agents; Body Weight; Ciprofloxacin; Dogs; Eating; Fluoroquinolones; Joint Diseases; Male; Ofloxacin; Piperazines; Synovial Fluid	1999
Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. The Journal of antimicrobial chemotherapy, 1999, Volume: 44, Issue:5 Topics: Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Macrophages; Microbial Sensitivity Tests; Monocytes; Mycobacterium; Mycobacterium avium Complex; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Piperazines; Tuberculosis	1999
Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin. Journal of medical microbiology, 1999, Volume: 48, Issue:12 Topics: Anti-Infective Agents; Ciprofloxacin; Deoxyribonucleases, Type II Site-Specific; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Piperazines; Pneumococcal Infections; Polymorphism, Restriction Fragment Length; Sequence Analysis, DNA; Streptococcus pneumoniae	1999
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:3 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines	2000
Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration. European journal of pharmacology, 2000, Oct-20, Volume: 406, Issue:3 Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dogs; Female; Fluoroquinolones; Heart; Male; Moxifloxacin; Piperazines; Quinolines; Time Factors	2000
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors	2001
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance. International journal of antimicrobial agents, 2001, Volume: 17, Issue:5 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae	2001
Safety of the new fluoroquinolones compared with ciprofloxacin. Journal of chemotherapy (Florence, Italy), 2000, Volume: 12 Suppl 1 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines	2000
Effects of new quinolones on transepithelial electrical potential difference of tracheal mucosa in vivo. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10 Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dogs; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Membrane Potentials; Piperazines; Trachea	2001
Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity. Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2 Topics: Anti-Infective Agents; Ciprofloxacin; DNA Gyrase; Drug Delivery Systems; Fluoroquinolones; Molecular Conformation; Piperazines; Streptococcus pneumoniae	2002
Comparative uptake of grepafloxacin and ciprofloxacin by a human monocytic cell line, THP-1. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2000, Volume: 6, Issue:3 Topics: Anti-Infective Agents; Cell Line; Ciprofloxacin; Fluoroquinolones; Humans; Monocytes; Piperazines	2000
Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2001, Volume: 20, Issue:12 Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Streptococcus pneumoniae	2001
Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. British journal of pharmacology, 2002, Volume: 135, Issue:5 Topics: Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Ciprofloxacin; Fluoroquinolones; Humans; Intestinal Mucosa; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Piperazines; Transfection	2002
Determination of lipophilicity of two quinolone antibacterials, ciprofloxacin and grepafloxacin, in the protonation equilibrium. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2002, Volume: 54, Issue:1 Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Piperazines; Structure-Activity Relationship	2002
Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2003, Volume: 55, Issue:2 Topics: Animals; Anti-Infective Agents; Biological Availability; Caco-2 Cells; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Carriers; Fluoroquinolones; Humans; In Vitro Techniques; Intestinal Absorption; Male; Models, Biological; Piperazines; Rats; Rats, Wistar	2003
Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin. International journal of pharmaceutics, 2006, Jan-03, Volume: 307, Issue:1 Topics: Animals; Anti-Infective Agents; Caco-2 Cells; Cell Membrane Permeability; Ciprofloxacin; Diffusion; Fluoroquinolones; Humans; Intestinal Absorption; Intestine, Small; Male; Models, Biological; Perfusion; Piperazines; Rats; Rats, Wistar	2006
The inhibitory effects of fluoroquinolones on L-carnitine transport in placental cell line BeWo. International journal of pharmaceutics, 2008, Mar-03, Volume: 351, Issue:1-2 Topics: Biological Transport; Carnitine; Cell Line, Tumor; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Ofloxacin; Organic Cation Transport Proteins; Piperazines; Placenta; Sodium; Solute Carrier Family 22 Member 5	2008
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:7 Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Biopharmaceutics; Bronchoalveolar Lavage Fluid; Cell Line; Ciprofloxacin; Fluoroquinolones; Humans; Macrophages, Alveolar; Male; Moxifloxacin; Piperazines; Rats; Rats, Sprague-Dawley; Urea	2014